Pfizer
NEWS
Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.
Pfizer’s La Jolla cancer research center is set to grow by about 100 people. The pharma giant is transferring employees from a recently shuttered South San Francisco immunology site to bolster the work conducted near San Diego.
With the closure of another year just weeks ahead, this time of year is one that many people use to take a look behind and see what lessons were learned over the past 12 months. For the world of biopharma, it’s also important to see what lessons have been learned.
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the report does believe there are good reasons to be.
RETACRIT to be Priced 57.1% Below the Wholesale Acquisition Cost (WAC) of Procrit® (epoetin alfa) and 33.5% Below the WAC of Epogen® (epoetin alfa)
An ovarian cancer treatment co-developed by Germany’s Merck KGaA and Pfizer failed to meet endpoints for overall survival and progression-free survival in a Phase III trial.
Six months after rolling back proposed price increases following a public rebuke by President Donald Trump, Pfizer will raise the price of 41 prescription drugs in January.
Viagra (sildenafil), Pfizer’s blockbuster drug for erectile dysfunction, is a classic example of how a drug developed for one thing can turn out to be successful for another.
JOBS
IN THE PRESS